利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.026 秒)

    Cassette for expressing a toxoplasma gondii P30 protein
    1.
    发明授权
    Cassette for expressing a toxoplasma gondii P30 protein 失效
    用于表达弓形体弓形虫P30蛋白的盒

    公开(公告)号：US06372443B1

    公开(公告)日：2002-04-16

    申请号：US08604986

    申请日：1996-03-13

    申请人： Eric Jacobs ,  Nathalie Silvestre ,  Bruno Mougin ,  Odette Bissardon ,  Michel Jolivet

    发明人： Eric Jacobs ,  Nathalie Silvestre ,  Bruno Mougin ,  Odette Bissardon ,  Michel Jolivet

    IPC分类号： G01N3353

    CPC分类号： C07K14/45 ,  A61K38/00 ,  A61K39/00 ,  C07K2319/02 ,  Y10S435/962

    摘要： The present invention provides a reagent for the detection or monitoring of a Toxoplasma gondii infection, which includes as a reactive substance a truncated Toxoplasma gondii P30 protein in which all of the hydrophobic C-terminal region of the native protein starting with the amino acid positioned after the amino acid 299 (SEQ ID NO: 1) has been deleted and all of the region of the native protein having the sequence starting with amino acid 31 and ending with the amino acid 299 (SEQ ID NO: 1) is contained. The present invention further describes methods of screening for anti-Toxoplasma antibodies in a biological sample.

    摘要翻译： 本发明提供了一种用于检测或监测弓形虫感染的试剂，其包括作为活性物质的截短弓形弓形体P30蛋白，其中天然蛋白质的所有疏水C末端区域以位于其后的氨基酸开始 已经缺失氨基酸299（SEQ ID NO：1），并且包含具有以氨基酸31开始并以氨基酸299（SEQ ID NO：1）结尾的序列的天然蛋白质的所有区域。 本发明还描述了在生物样品中筛选抗弓形体抗体的方法。

    METHOD FOR DETERMINING A BIOLOGICAL PATHWAY ACTIVITY
    2.
    发明申请
    METHOD FOR DETERMINING A BIOLOGICAL PATHWAY ACTIVITY 审中-公开
    确定生物路径活动的方法

    公开(公告)号：US20130210670A1

    公开(公告)日：2013-08-15

    申请号：US13878368

    申请日：2011-09-19

    申请人： Pierre Miossec ,  Bruno Mougin ,  Malick Paye ,  Frederic Reynier

    发明人： Pierre Miossec ,  Bruno Mougin ,  Malick Paye ,  Frederic Reynier

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/158

    摘要： Method for determining a level of activity of a biological pathway from a biological sample of a patient suffering from a pathology, the method comprising the steps of: measuring the level of expression of at least three genes from a group of individuals, control individuals or patients, for which the biological pathway is inactive, the at least three genes being associated to the biological pathway, for establishing a negative reference, and measuring level of expression of the at least three genes from a group of individuals, control individuals or patients, for which the biological pathway is active, for establishing a positive reference, and measuring the level of expression of the at least three genes of the patient in the sample.

    摘要翻译： 用于确定患有病理学的患者的生物学样品的生物学途径的活性水平的方法，所述方法包括以下步骤：测量来自一组个体，对照个体或患者的至少三种基因的表达水平 ，所述生物学途径不活跃，所述至少三种与生物学途径相关的基因，用于建立负参考，以及测量来自一组个体，对照个体或患者的至少三种基因的表达水平，用于 其生物学途径是活性的，用于建立阳性参考，以及测量样品中患者的至少三种基因的表达水平。

    Method and kit for the prognosis of colorectal cancer
    4.
    发明授权
    Method and kit for the prognosis of colorectal cancer 有权
    结直肠癌预后的方法和试剂盒

    公开(公告)号：US09422598B2

    公开(公告)日：2016-08-23

    申请号：US13698219

    申请日：2010-06-04

    申请人： Xun Ye ,  Fei Wu ,  Qinghua Xu ,  Xia Meng ,  Bruno Mougin ,  Fang Liu

    发明人： Xun Ye ,  Fei Wu ,  Qinghua Xu ,  Xia Meng ,  Bruno Mougin ,  Fang Liu

    IPC分类号： C07H21/04 ,  C12Q1/68 ,  C40B40/06

    CPC分类号： C12Q1/6886 ,  C12Q1/6837 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158 ,  C40B40/06

    摘要： A method and kit for the prognosis of colorectal cancer where the method includes the steps of: a) obtaining a peripheral blood sample and extracting total RNA from the sample, b) contacting the total RNA with at least one reagent specific for at least one NK cell gene and no more than 25 specific reagents for 25 NK cell genes, c) determining the expression level of at least one and at most 25 NK cell genes to obtain an expression profile for the patient, d) analyzing the expression profile with expression profiles previously clinically classified as a good prognosis and as a poor prognosis, wherein if the expression profile is clustered with the poor prognosis profiles, then the patient is determined to have a poor prognosis, and if the expression profile is clustered with the good prognosis profiles, then the patient is determined to have a good prognosis.

    摘要翻译： 一种用于结肠直肠癌预后的方法和试剂盒，其中所述方法包括以下步骤：a）获得外周血样品并从样品中提取总RNA，b）使总RNA与至少一种特异于至少一种NK的试剂接触 细胞基因和不超过25个特异性试剂用于25个NK细胞基因，c）确定至少一个和至多25个NK细胞基因的表达水平以获得患者的表达谱，d）用表达谱分析表达谱 以前临床分类为良好的预后和不良预后，其中如果表达谱具有不良预后特征，则确定患者的预后不良，并且如果表达谱具有良好的预后特征， 那么确定患者有良好的预后。

    METHOD AND KIT FOR THE PROGNOSIS OF COLORECTAL CANCER
    5.
    发明申请
    METHOD AND KIT FOR THE PROGNOSIS OF COLORECTAL CANCER 有权
    用于预防癌症的方法和工具包

    公开(公告)号：US20130072401A1

    公开(公告)日：2013-03-21

    申请号：US13698219

    申请日：2010-06-04

    申请人： Xun Ye ,  Fei Wu ,  Qinghua Xu ,  Xia Meng ,  Bruno Mougin ,  Fang Liu

    发明人： Xun Ye ,  Fei Wu ,  Qinghua Xu ,  Xia Meng ,  Bruno Mougin ,  Fang Liu

    IPC分类号： C12Q1/68 ,  C40B40/06

    CPC分类号： C12Q1/6886 ,  C12Q1/6837 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158 ,  C40B40/06

    摘要： A method and kit for the prognosis of colorectal cancer where the method includes the steps of: a) obtaining a peripheral blood sample and extracting total RNA from the sample, b) contacting the total RNA with at least one reagent specific for at least one NK cell gene and no more than 25 specific reagents for 25 NK cell genes, c) determining the expression level of at least one and at most 25 NK cell genes to obtain an expression profile for the patient, d) analyzing the expression profile with expression profiles previously clinically classified as a good prognosis and as a poor prognosis, wherein if the expression profile is clustered with the poor prognosis profiles, then the patient is determined to have a poor prognosis, and if the expression profile is clustered with the good prognosis profiles, then the patient is determined to have a good prognosis.

    摘要翻译： 一种用于结肠直肠癌预后的方法和试剂盒，其中所述方法包括以下步骤：a）获得外周血样品并从样品中提取总RNA，b）使总RNA与至少一种特异于至少一种NK的试剂接触 细胞基因和不超过25个特异性试剂用于25个NK细胞基因，c）确定至少一个和至多25个NK细胞基因的表达水平以获得患者的表达谱，d）用表达谱分析表达谱 以前临床分类为良好的预后和不良预后，其中如果表达谱具有不良预后特征，则确定患者的预后不良，并且如果表达谱具有良好的预后特征， 那么确定患者有良好的预后。

    Method for Breast Cancer Diagnosis
    7.
    发明申请
    Method for Breast Cancer Diagnosis 审中-公开
    乳腺癌诊断方法

    公开(公告)号：US20090123924A1

    公开(公告)日：2009-05-14

    申请号：US11988364

    申请日：2006-07-05

    申请人： Alexander Krause ,  Philippe Leissner ,  Bruno Mougin ,  Malick Paye

    发明人： Alexander Krause ,  Philippe Leissner ,  Bruno Mougin ,  Malick Paye

    IPC分类号： C12Q1/68 ,  C07H21/04

    CPC分类号： C12Q1/6886 ,  C12Q2600/178

    摘要： The invention relates to a method for the in vitro diagnosis of breast cancer in a patient who may be suffering from a breast cancer, characterized in that it comprises the following steps: a) biological material is extracted from a biological sample taken from the patient, b) the biological material is brought into contact with at least 8 specific reagents chosen from the specific reagents for the target genes with a nucleic sequence having any one of SEQ ID Nos. 1 to 8, c) the expression of said target genes is determined.

    摘要翻译： 本发明涉及可能患有乳腺癌的患者体外诊断乳腺癌的方法，其特征在于其包括以下步骤：a）从取自患者的生物样品中提取生物材料， b）生物材料与选自具有SEQ ID No.1至8中任一个的核酸序列的目标基因的特定试剂的至少8种特异性试剂接触，c）确定所述靶基因的表达 。

    Method for analyzing a patient's genetic prediposition to at least one disease and amplification adapted to such a method
    9.
    发明授权
    Method for analyzing a patient's genetic prediposition to at least one disease and amplification adapted to such a method 失效
    用于分析患者至少一种疾病的遗传倾向的方法和适用于该方法的扩增

    公开(公告)号：US07060438B1

    公开(公告)日：2006-06-13

    申请号：US09979088

    申请日：2000-05-19

    申请人： Bruno Mougin ,  Jean-Marie Tiercy

    发明人： Bruno Mougin ,  Jean-Marie Tiercy

    IPC分类号： C12Q1/68 ,  C12P19/34

    CPC分类号： C12Q1/6881 ,  C12Q2600/156 ,  C12Q2600/16

    摘要： A patient's genetic predisposition to a disease may be analyzed by placing, in the presence of probes, at least one type of amplicon, derived from the amplification of at least one polymorphic region of nucleic acid from the patient. The polymorphic region is a polymorphic region of interest with respect to the disease(s) being sought. The probes include at least one specific “low-resolution” typing probe that has the ability to hybridize to the polymorphic region of interest of at least one gene or a group of alleles of this gene carried by the amplicon and associated with the disease(s); and at least one specific “high-resolution” subtyping probe that has the ability to hybridize to the polymorphic region of interest of the allele or of the group of alleles specific for the “low-resolution” typing probe, the high-resolution probe(s) making it possible to distinguish the allele(s) associated with susceptibility and/or the allele(s) associated with resistance to the disease(s), according to whether or not they hybridize.

    摘要翻译： 患者对疾病的遗传易感性可以通过在探针存在下放置至少一种衍生自来自患者的核酸的至少一个多态性区域的扩增的扩增子来分析。 多态性区域是关于所寻求的疾病的感兴趣的多态性区域。 探针包括至少一种特异性“低分辨率”型分型探针，该探针具有与扩增子携带并与疾病相关的至少一种基因或该基因等位基因组的等位基因的多态性区域杂交的能力 ）; 和至少一种特异的“高分辨率”亚型分析探针，其具有与等位基因的多态性区域或“低分辨率”分型探针特异的等位基因组杂交的能力，高分辨率探针 s）使得可以根据它们是否杂交来区分与易感性相关的等位基因和/或与疾病的抗性相关的等位基因。